| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Leishmaniasis is endemic in 88 countries, with a total of 350 million people at risk. The incidence of leishmaniasis is increasing on a global level due to population and environmental changes.3 Depending on the type of parasite and the immune response of the patient, Leishmania species may cause a wide spectrum of disease including cutaneous (acute, chronic, recidiva, and disseminated anergic forms) and visceral forms with prevalence of over 12 million people worldwide and 1.5 to 2 million new cases each year.3–5
Cutaneous leishmaniasis has many different clinical presentations. Recently, there has been an increase in the number of reports for new and rare variants of CL.5–8
A rare and unusual presentation of CL is the erysipeloid type, which has been reported from Iran, Pakistan, and Turkey.6,9,10 This clinical form is not only unusual in its clinical features, but also in the specific category of patients whom it seems to afflict.11
We described a 73-year-old woman who has erysipeloid type CL presented with ulceration on glabellar region and infiltrative erythematous lesions covering the center of the face, resembling erysipelas in a nonendemic area of Turkey.
Erythematous lesion was reported to have enlarged and spread on her nose, cheeks, and forehead despite local and oral treatment with numerous antibiotics in the past 3 months. There was no history of trauma or insect bite. She had no significant past medical history. She denied having fever, chill, night sweating, weight loss, facial trauma, or traveling to an endemic area for CL.
Upon physical examination, a sharply defined erythematous indurated plaque with a central crusted ulcer on glabella, spreading to forehead, upper portion of the nose, and both cheeks was observed (Figure 1
). No other systemic abnormalities were detected.
|
) with Giemsa stain. Biopsy of the primary lesion showed a dense mixed inflammatory infiltrate in the upper dermis comprising lymphocytes and neutrophils. However, no organisms were identified.
|
).
|
In the course of typical CL, lesions start as small erythematous papules, which gradually enlarge to 1–2 cm in diameter in about 6 months and then ulcerate. These ulcers are painless with necrotic base and indurated margin and are frequently covered by a firmly adherent crust. Approximately 85% of skin lesions locate on the exposed body sites such as head, neck, arms, wrists, and hands.1,12
Cutaneous leishmaniasis shows a variety of morphologic patterns depending on the immune status of the host and subspecies of Leishmania. Atypical forms of CL such as psoriasiform, paronychial, sporotrichoid, impetiginized, palmoplantar, chancriform, zosteriform, annular, eczematoid, and verrucous types, may be seen very rarely.6–8
The other rare and unusual presentation of CL is the erysipeloid type. The reason for this unusual clinical type is unknown, although an altered host immune response, specific subtypes of parasite, hormonal factors and skin barrier changes, which emerge by skin fragility of the face, especially over the cheeks and nose due to senility can be speculated as the important points. No direct correlation has been reported with age, sex, and clinical features of CL except for the erysipeloid type, which seems to predominantly affect middle-aged and elderly females. It can be considered that a hormonal factor might have played some role in the causation of this rare clinical presentation.9,11,13 Development of erysipelas like lesions in CL may be explained by cell-mediated hypersensitivity as observed in other cutaneous infections or infestations.
Erysipeloid type CL was first reported from Iran in 1994 on the face of female patients predominantly.9 In 1998, Raja reported an erysipeloid form, presented as an erythematous, indurated, ill-defined plaque over the right side of the upper lip and adjacent cheek during a 6-month period.6 Salmanpour reported 5 Iranian patients, predominantly females, between 50 and 70 years of age, presented with infiltrative erythematous lesions covering the center of the face and resembling erysipelas.11 Karincaoglu described erysipeloid-type CL from Turkey in 2004 in a 60-year-old woman, presented with butterfly-shaped infiltrated erythematous plaque on the face,10 a case very similar to ours.
Clinically, localized cutaneous lesions can resemble bacterial skin infections, blastomycosis, sporotrichosis, cutaneous anthrax, eczema, fungal skin infections, leprosy, Mycobacterium marinum infections, sarcoidosis, basal and squamous cell carcinomas, tuberculosis, infected insect bites, and cutaneous metastasis of internal malignancies.3,4,7 When the plaque lesion of CL locates on face, systemic lupus erythematosus, discoid lupus erythematosus, sarcoidosis, lupus vulgaris, and erysipelas must be taken into consideration in the differential diagnosis.10,14
The diagnosis is confirmed by the demonstration of amastigotes in a Giemsa-stained smear. When the parasite cannot be detected on smear, Nicolle-Novy-McNeal medium culture, histopathologic examination, and/or leishmanin skin tests can be used. The Montenegro skin test uses leishmanial antigen to induce a cell-mediated response. Polymerase chain reaction—currently a research tool—appears to be the most sensitive single diagnostic test for CL.3,4,14
Although most CL lesions are self-limiting and may heal spontaneously within 1 to 5 years, treatment of CL should be performed in early and multiple, mucosal, or disseminated lesions, also for lesions involving cosmetically sensitive sites and those of immunosuppressed patients.15
There are various treatment options for CL such as pentavalent antimony compound, cryotherapy, topical parmomycin, local heat, curettage and surgical excision, electrodissection, CO2 laser, and the antifungal imidazole compounds such as ketoconazole, clotrimazole, miconazole, fluconazole, and itraconazole depending on the clinical type, localization, and diameter of the lesion. The pentavalent antimony compounds still remain the mainstay of the treatment in the majority of cases.3,14 Systemic meglumine antimoniate, 10 mg/kg/day intramuscularly for 20 days was administered in the present case. Ulcerated and eryhtematous lesions were healed almost completely by this regimen.
Considering the different forms of the disease nature, any unusual skin lesion located on the face, resembling erysipelas in a nonendemic area should always be investigated for CL and thus, atypical leishmaniasis should be kept in mind.
Received October 24, 2007. Accepted for publication December 7, 2007.
* Address correspondence to Ali M. Ceyhan, Suleyman Demirel University, School of Medicine, Department of Dermatology, Isparta, 32200, Turkey. E-mail: amuratceyhan{at}yahoo.com 
Authors’ addresses: Ali M. Ceyhan, Mehmet Yildirim, Pinar Y. Basak, Vahide B. Akkaya, and Ijlal Erturan, Suleyman Demirel University, School of Medicine, Department of Dermatology, Isparta, 32200, Turkey. E-mails: amuratceyhan{at}yahoo.com, yildirim{at}med.sdu.edu.tr, pbasak{at}med.sdu.edu.tr, vahide{at}med.sdu.edu.tr, and Ijlalerturan{at}mynet.com.
This article has been cited by other articles:
|
|
 |
|
  S. Mings, J. C. Beck, C. Davidson, A. L. Ondo, S. D. Shanler, and J. Berman Cutaneous Leishmaniasis with Boggy Induration and Simultaneous Mucosal Disease Am J Trop Med Hyg, January 1, 2009; 80(1): 3 - 5. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
